Related Experiment Video
Updated: Apr 29, 2026
06:07
Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
Published on: June 23, 2023
2.4K
The difference in putamen volume between MSA and PD: evidence from a meta-analysis
Wataru Sako1, Nagahisa Murakami2, Yuishin Izumi2
1Department of Clinical Neuroscience, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan; Center for Neurosciences, The Feinstein Institute for Medical Research, Manhasset, NY, USA.
Parkinsonism & Related Disorders
|May 22, 2014
Summary
Putamen volume is significantly reduced in multiple system atrophy (MSA) compared to Parkinson's disease (PD). This MRI-based finding aids early differential diagnosis for clinical trials.
Area of Science:
- Neuroimaging
- Neurodegenerative Diseases
- Clinical Diagnostics
Background:
- Accurate, non-invasive tools are crucial for early differential diagnosis between multiple system atrophy (MSA) and Parkinson's disease (PD).
- Magnetic Resonance Imaging (MRI) offers a more accessible alternative to Positron Emission Tomography (PET) for diagnostic purposes.
- Investigating putamen volume changes can aid in distinguishing these conditions.
Purpose of the Study:
- To meta-analyze the effect of MSA and PD on putamen volume.
- To evaluate the potential of putamen volumetry as a diagnostic tool.
- To inform patient selection for disease-modifying therapy clinical trials.
Main Methods:
- A meta-analysis was conducted on 6 eligible studies.
- Putamen volume differences between MSA and PD patients were expressed as standardized mean differences.
- Subgroup analyses were performed to explore heterogeneity, including factors like Hoehn-Yahr stage.
Main Results:
- Putamen volume was significantly more reduced in MSA patients compared to PD patients (P = 0.0004).
- The meta-analysis included 84 MSA and 180 PD patients across 6 studies, revealing significant heterogeneity (I(2) = 87%).
- Subgroup analysis indicated that the Hoehn-Yahr stage of PD significantly influenced the results (P = 0.003).
Conclusions:
- Putamen volumetry, assessed via MRI, shows promise for differentiating early-stage MSA from PD.
- This imaging biomarker can facilitate more accurate patient stratification in clinical trials for neurodegenerative diseases.
- The findings support the use of putamen volume as a diagnostic aid and for optimizing clinical trial enrollment.
